Zanidatamab plus chemotherapy before and after surgery for her2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether adding a new targeted drug called zanidatamab to standard chemotherapy before and after surgery can improve the chances of getting rid of HER2-positive stomach or esophageal cancer. It is designed for patients whose cancer can still be removed with surgery and has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have HER2-positive stomach, esophageal, or gastroesophageal cancer that has not spread to other parts of the body and can be removed with surgery.
- You have not had chemotherapy or radiation before surgery for this cancer.
- You are in good general health (able to do light activity like walking).
- Your heart, liver, kidneys, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with advanced HER2-positive stomach or gastroesophageal cancer feel and function while receiving zanidatamab as their first treatment. It aims to understand the real-world experiences and outcomes of this therapy.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests a new drug called zanidatamab given together with standard chemotherapy before surgery for a type of stomach or junction cancer that is HER2-positive (has a specific protein). The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Hear when a new GastroEsophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.